Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

Inclusion Criteria: * Subjects ≥ 50 years of age at baseline * Subjects diagnosed with nAMD (uni- or bilateral) * Subjects already under IVT Eylea treatment (last injection of the induction period or maintenance phase) Exclusion Criteria: * Active or recent (within 4 weeks) intraocular inflammation (grade trace or above) in the study eye at baseline, which is of clinical significance according to the investigator's judgment, such as active infections of the anterior segment; this includes conjunctivitis (except mild blepharitis), keratitis, scleritis, idiopathic or autoimmune associated uveitis or endophthalmitis * Any uncontrolled ocular hypertension or glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 26 mmHg, despite treatment with anti-glaucomatous medication) * History of a medical, ocular or non-ocular condition, that in the judgment of the investigator, would preclude a safe administration of investigational product * Visual Acuity Score (VAS) worse than 20/200 on a Snellen chart, the generally accepted level of legal blindness * Receipt of any systemic anti-VEGF within the last 6 months prior to enrollment * Uncontrolled hypertension (defined as a systolic value ≥ 160 mmHg or diastolic value ≥ 100 mmHg at Screening) * Subjects who do not comply with the local COVID-19 regulations of the study site